Advertisement

Japanese Journal of Ophthalmology

, Volume 63, Issue 4, pp 322–327 | Cite as

Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series

  • Hee Jung Joh
  • Sang Wook JinEmail author
Clinical Investigation
  • 91 Downloads

Abstract

Purpose

To compare the efficacy and safety of two combinations of maximum medical therapy for lowering intraocular pressure (IOP) in primary open angle glaucoma (POAG).

Study design

A retrospective consecutive case series.

Methods

A retrospective consecutive case series study including 82 eyes of 82 subjects with POAG treated with maximum medical therapy to lower IOP. Enrolled patients were divided into 2 groups: the triple maximum medical therapy (TMT) group, comprising POAG patients who were treated with tafluprost, brimonidine and the fixed drug combination (FDC) brinzolamide/timolol; and the double maximum medical therapy (DMT) group, comprising POAG patients who were treated with the FDCs tafluprost/timolol and brinzolamide/brimonidine. We compared the demographics, baseline IOP, IOP reduction rate, and adverse drug reactions (ADRs) between the 2 groups.

Results

While the mean IOP reduction rate after 12 months was higher in the TMT group (52.7%) than in the DMT group (50.4%), the difference was not significant (p-value = 0.615). In the TMT group, the rate of proceeding to laser or surgical therapy was 22.2% (DMT group = 37.8%). In the TMT group, the time duration between beginning maximum medical therapy and proceeding to laser or surgical therapy was 10.7 ± 1.3 months (DMT group = 10.3 ± 1.5 months). No serious ADRs were reported in either group. However, the incidence rate of conjunctival hyperemia and dry eye was significantly lower in the DMT group than in the TMT group.

Conclusion

DMT is safe and effective for lowering IOP in POAG patients. DMT is not inferior to TMT in POAG patients.

Keywords

Maximum medical therapy Primary open angle glaucoma Intraocular pressure 

Notes

Acknowledgements

This work was supported by Dong-A University Research Fund. The authors thank American Journal Experts (http://www.journalexperts.com) for providing editing services for this manuscript.

Conflicts of interest

H. J. Joh, None; S. W. Jin, None.

References

  1. 1.
    European Glaucoma Society. Terminology and guidelines for glaucoma, 4th edition, http://bjo.bmj.com/content/bjophthalmol/101/4/1.full.pdf.
  2. 2.
    American Academy of Ophthalmology Glaucoma Panel. Preferred practice pattern guidelines. Primary open angle glaucoma. San Francisco: American Academy of Ophthalmology; 2010.Google Scholar
  3. 3.
    Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging. 2008;25:729–59.CrossRefGoogle Scholar
  4. 4.
    Quigley HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol. 1994;112:644–9.CrossRefGoogle Scholar
  5. 5.
    Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, et al. The ocular hyperten-sion treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.CrossRefGoogle Scholar
  6. 6.
    Inoue K, Ishida K, Tomita G. Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil. Jpn J Ophthalmol. 2018;62:508–16.CrossRefGoogle Scholar
  7. 7.
    Komizo T, Ono T, Yagi A, Miyata K, Aihara M. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma. Jpn J Ophthalmol. 2019;63:40–5.CrossRefGoogle Scholar
  8. 8.
    Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Opththalmol. 2008;53(Suppl 1):S57–68.CrossRefGoogle Scholar
  9. 9.
    Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, Mallick S, Landry TA, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1–7.CrossRefGoogle Scholar
  10. 10.
    Lee AJ, McCluskey P. Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. Clin Ophthalmol. 2008;2:545–55.CrossRefGoogle Scholar
  11. 11.
    Inoue K, Shiokawa M, Sugahara M, Wakakura M, Soeda S, Tomita G. Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn J Ophthalmol. 2012;56:559–63.CrossRefGoogle Scholar
  12. 12.
    Tham CC, Kwong YY, Leung DY, Lam SW, Li FC, Chiu TY, et al. Phacoemulsification versus combined phacotrabeculectomy in medically uncontrolled chronic angle closure glaucoma with cataracts. Ophthalmology. 2009;116:725–31.CrossRefGoogle Scholar
  13. 13.
    Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25:900–7.CrossRefGoogle Scholar
  14. 14.
    The DEWS Definition and Classification Subcommittee. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007;5:75–92.CrossRefGoogle Scholar
  15. 15.
    Holló G, Hommer A, Antón López A, Ropo A. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Ther. 2014;30:468–75.CrossRefGoogle Scholar
  16. 16.
    Inoue K, Kawashima T, Katakura S, Shidara K, Fujimoto T, Kohmoto H, et al. Switching from concomitant therapy to tafluprost/timolol fixed combination. Clin Ophthalmol. 2018;12:549–54.CrossRefGoogle Scholar
  17. 17.
    Jin SW, Lee SM. The efficacy and safety of the fixed combination of brinzolamide 1% and brimonidine 02% in normal tension glaucoma: an 18-month retrospective study. J Ocul Pharmacol Ther. 2018;34:274–9.CrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2019

Authors and Affiliations

  1. 1.Department of OphthalmologyDong-A University College of MedicineBusanRepublic of Korea

Personalised recommendations